TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the closing of Teva's acquisition of Emalex Biosciences, strengthening its late- stage pipeline with ecopipam and further advancing its Pivot to Growth strategy. Phase 3 data for ecopipam were recently published in JAMA Neurology, and a U.S. NDA submission is anticipated in the second half of 2026. "This acquisition reflects our Pivot to Growth strategy in action, advancing our inno ...

公司战略与运营调整 - 梯瓦制药旗下原料药部门TAPI宣布进行运营调整，以支持一项长期增长战略[1] - 调整过程将包括人员削减[1] - 公司曾就出售其原料药业务进行谈判，但交易未能达成[1] 人员裁减计划详情 - 未来两年内，TAPI在以色列的整个部门将逐步裁减约250个工作岗位[2] - 此次裁员主要将影响位于贝尔谢巴附近Neot Hovav的Teva Tech工厂[2] - TAPI在全球拥有4,100名员工，其中在以色列有650名员工[2] 计划执行与沟通 - 该举措是在与员工代表和以色列总工会的充分协调与合作下进行的[2] - 此举旨在从长远角度加强该部门在以色列的运营稳定性[2]